Percutaneous Coronary Intervention

Eptifibatide Injection Reduces Major Ischemic Complications

Published in Blood Weekly, January 11th, 2001

COR Therapeutics, Inc., announced December 14, 2000, the publication of 48-hour and 30-day results from the ESPRIT study, which demonstrated statistically and clinically significant improvements in outcomes in patients receiving Integrilin^R during non-emergency percutaneous coronary intervention (PCI).

Study data were published in the December 16, 2000, issue of the medical journal, The Lancet.

The study showed that when Integrilin was administered in addition to modern PCI techniques, which include the use of multiple intracoronary stents, even in small tortuous vessels, the combined incidence of death, myocardial infarction, need...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-01-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry